Your browser is no longer supported. Please, upgrade your browser.
Settings
JNCE Jounce Therapeutics, Inc. daily Stock Chart
JNCE [NASD]
Jounce Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.96 Insider Own0.40% Shs Outstand33.02M Perf Week-8.56%
Market Cap201.09M Forward P/E- EPS next Y-1.20 Insider Trans1.46% Shs Float27.65M Perf Month-9.51%
Income-31.20M PEG- EPS next Q-0.34 Inst Own82.70% Short Float12.23% Perf Quarter-22.22%
Sales61.60M P/S3.26 EPS this Y20.30% Inst Trans-0.09% Short Ratio12.12 Perf Half Y-68.67%
Book/sh3.34 P/B1.82 EPS next Y4.80% ROA-10.90% Target Price12.75 Perf Year-60.38%
Cash/sh7.05 P/C0.86 EPS next 5Y- ROE-22.20% 52W Range5.51 - 29.25 Perf YTD-52.24%
Dividend- P/FCF- EPS past 5Y- ROI-11.50% 52W High-79.18% Beta-
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low10.53% ATR0.43
Employees113 Current Ratio3.60 Sales Q/Q-4.40% Oper. Margin-57.20% RSI (14)40.56 Volatility8.01% 7.13%
OptionableYes Debt/Eq0.00 EPS Q/Q-36.80% Profit Margin-50.50% Rel Volume0.68 Prev Close5.69
ShortableYes LT Debt/Eq0.00 EarningsNov 08 BMO Payout- Avg Volume278.95K Price6.09
Recom2.30 SMA20-6.00% SMA50-14.35% SMA200-56.92% Volume190,965 Change7.03%
Jun-28-18Initiated Raymond James Outperform
May-17-18Downgrade Wells Fargo Outperform → Market Perform
Apr-27-18Initiated H.C. Wainwright Buy $33
Oct-01-18 11:39AM  Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation GlobeNewswire
Sep-26-18 08:00AM  Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Aug-29-18 08:00AM  Jounce Therapeutics to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-21-18 07:30AM  Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.50%
Aug-09-18 07:50AM  Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates Zacks +10.29%
06:30AM  Jounce Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
06:00AM  Jounce Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:00AM  Jounce Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018 GlobeNewswire
Jul-11-18 07:20AM  Free Technical Research on Intrexon and Three More Biotech Equities ACCESSWIRE
Jun-06-18 08:10AM  Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jun-05-18 12:04PM  Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason InvestorPlace
08:10AM  Today's Research Reports on Stocks to Watch: Deciphera Pharmaceuticals and Jounce Therapeutics ACCESSWIRE
Jun-04-18 02:13PM  Here's Why Jounce Therapeutics Fell Over 38% Today Motley Fool -33.48%
Jun-02-18 04:00PM  Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers GlobeNewswire
May-22-18 12:30PM  Recent Sell-Off in Jounce therapeutics (JNCE) Stock Is Unwarranted SmarterAnalyst
May-18-18 08:10AM  Todays Research Reports on Stocks to Watch: Loxo Oncology and Jounce Therapeutics ACCESSWIRE
May-17-18 06:07PM  Jounce Therapeutics Gets Throttled, Loses 35% Today Motley Fool -35.20%
04:40PM  Why J.C. Penney, NetEase, and Jounce Therapeutics Slumped Today Motley Fool
11:16AM  Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades Benzinga
May-16-18 05:01PM  Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting GlobeNewswire +6.45%
11:52AM  Edited Transcript of JNCE.O earnings conference call or presentation 9-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-09-18 06:30AM  Jounce Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire -15.23%
May-02-18 08:00AM  Jounce Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018 GlobeNewswire
May-01-18 08:00AM  Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference GlobeNewswire
Apr-12-18 08:00AM  Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire +6.45%
Apr-10-18 07:30AM  New Research Coverage Highlights YY, Orbotech, Green Plains Partners LP, Jounce Therapeutics, Carbonite, and Golar LNG Partners LP Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +7.43%
Apr-08-18 08:56AM  Biotech Fire Sale: 2 Top Stocks to Buy Next Week Motley Fool
Mar-16-18 07:45AM  Report: Exploring Fundamental Drivers Behind Gladstone Commercial, IRHYTHM TECH, Jounce Therapeutics, CoStar Group, Tecnoglass, and Merus N.V New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-09-18 07:31AM  Jounce Therapeutics Is on Track to Report Key Data Soon Motley Fool
Mar-08-18 10:16PM  Edited Transcript of JNCE.O earnings conference call or presentation 8-Mar-18 1:00pm GMT Thomson Reuters StreetEvents +19.41%
06:30AM  Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-05-18 08:00AM  Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 04:52PM  Jounce Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018 GlobeNewswire
Feb-04-18 08:01AM  3 Boom-or-Bust Biotech Stocks to Buy in 2018 Motley Fool
Jan-30-18 07:16AM  3 Top Stocks Wall Street Is Overlooking Motley Fool
Jan-26-18 11:57AM  Jounce Therapeutics, Inc. (Nasdaq: JNCE) to Ring the Nasdaq Stock Market Closing Bell GlobeNewswire
Jan-23-18 08:00AM  Celgene's Investments Are Soaring Motley Fool
Jan-22-18 11:43AM  Is Sanofis Bioverative Inc Buyout Just the Start? InvestorPlace
10:53AM  Why Celgene Corporation Stock Is ALL About the Buyouts InvestorPlace
Jan-20-18 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-19-18 08:31AM  Will This Tiny Biotech Be Celgene's Next Takeover Target? Motley Fool +11.76%
Jan-12-18 01:55PM  Edited Transcript of JNCE.O earnings conference call or presentation 13-Nov-17 1:00pm GMT Thomson Reuters StreetEvents +6.51%
10:47AM  Edited Transcript of JNCE.O earnings conference call or presentation 9-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
Jan-10-18 12:08PM  4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE) SmarterAnalyst +5.11%
Jan-03-18 08:00AM  Jounce Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +6.57%
Dec-14-17 07:00AM  Jounce Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-07-17 08:00AM  Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-05-17 07:47AM  Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : December 5, 2017 Capital Cube
Nov-24-17 11:24AM  Jounce Therapeutics, Inc. Value Analysis (NASDAQ:JNCE) : November 24, 2017 Capital Cube
Nov-23-17 07:15AM  Jounce Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : JNCE-US : November 23, 2017 Capital Cube
Nov-17-17 08:30AM  Can This Tiny Biotech Stock Pay Off Big for Celgene? Motley Fool
Nov-13-17 06:30AM  Jounce Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-09-17 08:00AM  Jounce Therapeutics to Present at the Stifel 2017 Healthcare Conference GlobeNewswire
Nov-08-17 08:00AM  Jounce Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 13, 2017 GlobeNewswire
Nov-07-17 08:00AM  Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting GlobeNewswire
Oct-23-17 08:00AM  Jounce Therapeutics Appoints Luis A. Diaz, Jr., M.D., to its Board of Directors GlobeNewswire
Oct-19-17 08:15AM  Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : October 19, 2017 Capital Cube
Aug-30-17 08:00AM  Jounce Therapeutics to Present at Upcoming Investor Conferences in September GlobeNewswire
Aug-28-17 08:52PM  Jounce Therapeutics, Inc. Value Analysis (NASDAQ:JNCE) : August 29, 2017 Capital Cube
Aug-18-17 09:43AM  Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : August 18, 2017 Capital Cube +6.97%
Aug-17-17 08:25AM  Jounce Therapeutics (JNCE) Jumps: Stock Moves 7.4% Higher Zacks -5.59%
Aug-15-17 08:00AM  Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development GlobeNewswire +6.04%
Aug-09-17 06:30AM  Jounce Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-02-17 08:00AM  Jounce Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9, 2017 GlobeNewswire
Jun-21-17 08:30AM  Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance Business Wire
Jun-18-17 09:07AM  3 Top Healthcare Stocks You Haven't Thought Of Motley Fool
Jun-12-17 06:01AM  OncoSec Announces Technology Access Program Agreement with Jounce Therapeutics, Inc. PR Newswire -5.91%
Jun-05-17 09:00AM  Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO Annual Meeting GlobeNewswire
May-19-17 02:31PM  Jounce Therapeutics, Inc. Value Analysis (NASDAQ:JNCE) : May 19, 2017 Capital Cube -6.33%
May-18-17 08:38AM  Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : May 18, 2017 Capital Cube
May-17-17 05:00PM  Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting GlobeNewswire -6.55%
May-09-17 08:00AM  Jounce Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
May-03-17 04:54AM  Will Jounce Therapeutics (JNCE) Continue to Surge Higher? Zacks
Apr-28-17 04:51AM  Merck KGaA says dominance in liquid crystals could be at risk Reuters +5.44%
Apr-20-17 04:01PM  Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors GlobeNewswire
Apr-14-17 08:24AM  Jounce Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JNCE-US : April 14, 2017 Capital Cube
Mar-31-17 04:01PM  Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes GlobeNewswire
Mar-30-17 12:35PM  Q1 IPOs Raised $10 Billion
Mar-22-17 04:01PM  Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program GlobeNewswire
Mar-16-17 01:04PM  JOUNCE THERAPEUTICS, INC. Financials
Mar-10-17 08:29AM  JOUNCE THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
08:00AM  Jounce Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Mar-06-17 01:00PM  New Cambridge-based, Third Rock-backed biotech revealed in federal filing at bizjournals.com +7.70%
01:00PM  New Cambridge-based, Third Rock-backed biotech revealed in federal filing American City Business Journals
Feb-28-17 08:00AM  Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-22-17 10:00AM  Lexington's Agenus quietly discloses failure of cancer vaccine trial at bizjournals.com
10:00AM  Lexington's Agenus quietly discloses failure of cancer vaccine trial American City Business Journals
Feb-21-17 06:12AM  Coverage initiated on Jounce Therapeutics by JP Morgan, Wells Fargo and Robert W. Baird
Feb-14-17 11:45AM  Lexington-based Agenus reworks Incyte pact, freeing up $80M in cash at bizjournals.com
11:45AM  Lexington-based Agenus reworks Incyte pact, freeing up $80M in cash American City Business Journals
Feb-06-17 12:31PM  Robust Start for Pharmaceutical IPOs In 2017 Investopedia
12:31PM  Robust Start for Pharmaceutical IPOs In 2017 at Investopedia
Feb-02-17 05:16PM  [$$] Braeburn Pharmaceuticals Puts IPO Plans On Hold The Wall Street Journal
05:16PM  [$$] Braeburn Pharmaceuticals Puts IPO Plans On Hold at The Wall Street Journal
04:23PM  Celgene Subsidiary Invests in Jounce Therapeutics
Jan-29-17 11:39PM  [$$] Shares in Two Biotechs Rise Post-IPO at The Wall Street Journal
09:38AM  IPO Market Looking for 7 Offerings This Week
Jan-27-17 04:37PM  Jounce Adds Juice To IPO Market After Unicorn AppDynamics Acquired
02:05PM  After $97M IPO, Swiss biotech to open U.S. headquarters in Boston at bizjournals.com
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MURRAY RICHARD /CA/CEO and PresidentSep 06Option Exercise0.4832,00015,36032,000Sep 07 04:48 PM
Drapkin Kimberlee CCFO and TreasurerAug 27Option Exercise2.3612,70029,97227,100Aug 28 05:28 PM
Cole Hugh MChief Business OfficerJun 15Buy7.841,90014,8961,900Jun 18 06:24 PM
Trehu ElizabethChief Medical OfficerJun 08Option Exercise4.0224,87599,99824,875Jun 12 06:01 PM
Duncan Barbara GayleDirectorMar 15Option Exercise4.212,0008,4202,000Mar 19 06:42 PM
Duncan Barbara GayleDirectorMar 15Sale28.112,00056,2200Mar 19 06:42 PM
Drapkin Kimberlee CCFO and TreasurerMar 08Option Exercise0.483,7591,8045,267Mar 12 07:06 PM
MURRAY RICHARD /CA/CEO and PresidentMar 08Option Exercise0.4816,3347,84016,334Mar 12 07:06 PM
Trehu ElizabethChief Medical OfficerMar 08Option Exercise4.024,54518,2714,545Mar 12 07:07 PM
Trehu ElizabethChief Medical OfficerMar 08Sale25.064,545113,8980Mar 12 07:07 PM
MURRAY RICHARD /CA/CEO and PresidentMar 08Sale25.1016,334409,9830Mar 12 07:06 PM
Drapkin Kimberlee CCFO and TreasurerMar 08Sale25.015,267131,7280Mar 12 07:06 PM
MURRAY RICHARD /CA/CEO and PresidentMar 05Option Exercise0.4816,3347,84016,334Mar 07 06:59 PM
Trehu ElizabethChief Medical OfficerMar 05Option Exercise4.024,54518,2714,545Mar 07 07:00 PM
Trehu ElizabethChief Medical OfficerMar 05Sale21.504,54597,7240Mar 07 07:00 PM
MURRAY RICHARD /CA/CEO and PresidentMar 05Sale21.4316,334350,0430Mar 07 06:59 PM
Drapkin Kimberlee CCFO and TreasurerMar 05Sale21.425,267112,8031,508Mar 07 06:57 PM
Duncan Barbara GayleDirectorJan 26Option Exercise4.214,00016,8404,000Jan 29 08:26 PM
Duncan Barbara GayleDirectorJan 26Sale25.004,000100,0000Jan 29 08:26 PM